Company intelligence / Profile preview
Vasculonics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Developing disease-modifying therapies for pulmonary arterial hypertension and other conditions. Currently in preclinical stage with grant validation including a Catalyze grant and an SBIR phase 2a for $2.1M starting at the end of 2024
- Therapeutic areas
- NephrologyOtherCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules (oral tablet VN-1032)Medical device (extracorporeal device VN-901)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Vasculonics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasculonics.